Literature DB >> 11046083

Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats.

H Xiong1, K C Turner, E S Ward, P L Jansen, K L Brouwer.   

Abstract

Previous studies have demonstrated that phenobarbital treatment impairs the biliary excretion of acetaminophen glucuronide (AG), although the transport system(s) responsible for AG excretion into bile has not been identified. Initial studies in rat canalicular liver plasma membrane vesicles indicated that AG uptake was stimulated modestly by ATP, but not by membrane potential, HCO(3)(-), or pH gradients. To examine the role of the ATP-dependent canalicular transporter multidrug resistance-associated protein 2 (Mrp2)/canalicular multispecific organic anion transporter (cMOAT) in the biliary excretion of AG, the hepatobiliary disposition of acetaminophen, AG, and acetaminophen sulfate (AS) was examined in isolated perfused livers from control and TR(-) (Mrp2-deficient) Wistar rats. Mean bile flow in TR(-) livers was approximately 0.3 microl/min/g of liver ( approximately 4-fold lower than control). AG biliary excretion was decreased (>300-fold) to negligible levels in TR(-) rat livers, indicating that AG is an Mrp2 substrate. Similarly, AS biliary excretion in TR(-) livers was decreased ( approximately 5-fold); however, concentrations were still measurable, suggesting that multiple mechanisms, including Mrp2-mediated active transport, may be involved in AS biliary excretion. AG and AS perfusate concentrations were significantly higher in livers from TR(-) compared with control rats. Pharmacokinetic modeling of the data revealed that the rate constant for basolateral egress of AG increased significantly from 0.028 to 0.206 min(-1), consistent with up-regulation of a basolateral organic anion transporter in Mrp2-deficient rat livers. In conclusion, these data indicate that AG biliary excretion is mediated by Mrp2, and clearly demonstrate that substrate disposition may be influenced by alterations in complementary transport systems in transport-deficient animals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046083

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Authors:  James J Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2018-11-30       Impact factor: 3.922

3.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

Review 4.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

5.  Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Matthew D Merrell; Rhiannon N Hardwick; Amy M Bataille; Sarah N Campion; Daniel W Ferreira; Stavra A Xanthakos; Jose E Manautou; H Hesham A-Kader; Robert P Erickson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2015-03-18       Impact factor: 3.922

Review 6.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

7.  Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters-in vitro and in vivo evidences.

Authors:  Li Zhang; Chenrui Li; Ge Lin; Peter Krajcsi; Zhong Zuo
Journal:  AAPS J       Date:  2011-05-24       Impact factor: 4.009

8.  Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Authors:  Jacqueline Bezençon; James J Beaudoin; Katsuaki Ito; Dong Fu; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-06-03       Impact factor: 3.922

9.  Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.

Authors:  María L Ruiz; Juan P Rigalli; Agostina Arias; Silvina Villanueva; Claudia Banchio; Mary Vore; Aldo D Mottino; Viviana A Catania
Journal:  Drug Metab Dispos       Date:  2012-10-17       Impact factor: 3.922

10.  Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.

Authors:  Xianbin Tian; Brandon Swift; Maciej J Zamek-Gliszczynski; Martin G Belinsky; Gary D Kruh; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-02-14       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.